Broadstreet Health Economics and Outcomes Research, commonly referred to as Broadstreet HEOR, is a leading firm headquartered in California, specialising in health economics, outcomes research, and real-world evidence generation. Founded in 2015, the company has rapidly established itself as a key player in the healthcare industry, providing innovative solutions that inform decision-making for pharmaceutical and biotechnology companies. Broadstreet HEOR offers a range of core services, including economic modelling, health technology assessments, and patient-reported outcomes analysis. Their unique approach combines advanced analytics with a deep understanding of healthcare systems, enabling clients to navigate complex market landscapes effectively. With a strong presence across major operational regions in North America and Europe, Broadstreet HEOR is recognised for its commitment to delivering high-quality, evidence-based insights that drive value in healthcare.
How does Broadstreet Health Economics And Outcomes Research's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Broadstreet Health Economics And Outcomes Research's score of 23 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Broadstreet Health Economics and Outcomes Research reported total carbon emissions of approximately 260,200 kg CO2e. This figure includes 5,400 kg CO2e from Scope 1 emissions, 800 kg CO2e from Scope 2 emissions, and a significant 254,000 kg CO2e from Scope 3 emissions. The organisation has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). Furthermore, there is no information available regarding any climate pledges. Historically, emissions data shows a notable increase in 2022, with total emissions reaching approximately 686,600 kg CO2e, primarily driven by Scope 1 and Scope 2 emissions. In 2021, Scope 1 emissions alone were reported at approximately 533 million kg CO2e, highlighting a significant environmental footprint. Broadstreet Health Economics and Outcomes Research operates from its headquarters in California and is currently not linked to any cascaded emissions data from a parent organisation. The absence of comprehensive climate commitments suggests an opportunity for the organisation to enhance its sustainability efforts and align with industry standards for carbon reduction.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | - | 000,000,000 | 000,000 |
| Scope 2 | - | - | 000,000 |
| Scope 3 | - | - | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Broadstreet Health Economics And Outcomes Research has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.